Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

被引：37

作者：

Paiva, Bruno ^{[1
]}

Vidriales, Maria-Belen ^{[2
,3
]}

Sempere, Amparo ^{[4
]}

Tarin, Fabian ^{[5
]}

Colado, Enrique ^{[6
,7
]}

Benavente, Celina ^{[8
]}

Cedena, Maria-Teresa ^{[9
]}

Sanchez, Joaquin ^{[10
]}

Caballero-Velazquez, Teresa ^{[11
]}

Cordon, Lourdes ^{[4
]}

Garces, Juan-Jose ^{[1
]}

Simoes, Catia ^{[1
]}

Martinez-Cuadron, David ^{[4
]}

Bernal, Teresa ^{[6
,7
]}

Botella, Carmen ^{[5
]}

Grille, Sofia ^{[12
]}

Serrano, Josefina ^{[10
]}

Rodriguez-Medina, Carlos ^{[13
]}

Algarra, Lorenzo ^{[14
]}

Alonso-Dominguez, Juan-Manuel ^{[15
]}

Amigo, Maria-Luz ^{[16
]}

Barrios, Manuel ^{[17
]}

Garcia-Boyero, Raimundo ^{[18
]}

Colorado, Mercedes ^{[19
]}

Perez-Oteyza, Jaime ^{[20
]}

Perez-Encinas, Manuel ^{[21
]}

Costilla-Barriga, Lisette ^{[22
]}

Sayas, Maria-Jose ^{[23
]}

Perez, Olga ^{[24
]}

Gonzalez-Diaz, Marcos ^{[2
]}

Perez-Simon, Jose A. ^{[11
]}

Martinez-Lopez, Joaquin ^{[8
,9
]}

Sossa, Claudia ^{[25
]}

Orfao, Alberto ^{[26
,27
,28
,29
,30
]}

San Miguel, Jesus F. ^{[1
]}

Sanz, Miguel-Angel ^{[3
,4
]}

Montesinos, Pau ^{[3
,4
]}

机构：

[1] Clin Univ Navarra, Ctr Invest Med Aplicada CIMA, IDISNA, CIBER ONC, CB16-12, Pamplona 00369, Spain

[2] Univ Hosp Salamanca HUS IBSAL, CIBERONC, Dept Hematol, CB16-12-002333, Salamanca, Spain

[3] USAL, CSIC, Ctr Canc Res IBMCC, Salamanca, Spain

[4] Hosp Univ & Politecn La Fe, CIBER ONC, CB16-12-00284, Valencia, Spain

[5] Hosp Gen Univ Alicante, Alicante, Spain

[6] Hosp Univ Cent Asturias, Inst Invest Sanitaria, Oviedo, Spain

[7] Univ Oncol Principado Asturias ISPA IUOPA, Oviedo, Spain

[8] Hosp Clin San Carlos, Madrid, Spain

[9] Hosp Univ 12 Octubre, Madrid, Spain

[10] Hosp Reina Sofia, Cordoba, Spain

[11] Univ Seville, CSIC, Hopsital Univ Virgen Rocio, Inst Biomed IBIS,CIBERONC, Seville, Spain

[12] Hosp Clin Montevideo, Uruguay, Uruguay

[13] Hosp Univ Gran Canaria Doctor Negrin, Las Palmas Gran Canaria, Spain

[14] Hosp Gen Albacete, Albacete, Spain

[15] Fdn Jimenez Diaz, Hosp Univ, Madrid, Spain

[16] Hosp Morales Messeguer, Murcia, Spain

[17] Hosp Reg Univ Malaga, Malaga, Spain

[18] Hosp Gen Univ Castellon, Castellon De La Plana, Spain

[19] Hosp Univ Marques Valdecilla, Santander, Spain

[20] Hosp HM Madrid, Madrid, Spain

[21] Hosp Clin Santiago De Compostela, Santiago De Compostela, Spain

[22] Hosp Miguel Servet, Zaragoza, Spain

[23] Hosp Univ Dr Peset, Valencia, Spain

[24] Hosp Univ Virgen Macarena, Seville, Spain

[25] Clin FOSCAL, Santander, Colombia

[26] Univ Salamanca, CSIC, Canc Res Ctr, IBMCC,USAL,IBSAL, Salamanca, Spain

[27] Univ Salamanca, Cytometry Serv NUCLEUS, Salamanca, Spain

[28] Univ Salamanca, Dept Med, Salamanca, Spain

[29] Inst Carlos III, USAL Ctr Invest Biomed Red Canc, Salamanca, Spain

[30] CIBER ONC, CB16-12-00400, Salamanca, Spain

[31] Fdn PETHEMA, Madrid, Spain

来源：

LEUKEMIA | 2021年 / 35卷 / 08期

关键词：

HEMATOPOIETIC-CELL TRANSPLANTATION; PROGNOSTIC IMPACT; TREATMENT RESPONSE; INDUCTION THERAPY; REDUCED-INTENSITY; RELAPSE RISK; AML; 1ST; REMISSION; DIAGNOSIS;

D O I：

10.1038/s41375-021-01126-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of decentralized assessment of measurable residual disease (MRD) for risk stratification in acute myeloid leukemia (AML) remains largely unknown, and so it does which methodological aspects are critical to empower the evaluation of MRD with prognostic significance, particularly if using multiparameter flow cytometry (MFC). We analyzed 1076 AML patients in first remission after induction chemotherapy, in whom MRD was evaluated by MFC in local laboratories of 60 Hospitals participating in the PETHEMA registry. We also conducted a survey on technical aspects of MRD testing to determine the impact of methodological heterogeneity in the prognostic value of MFC. Our results confirmed the recommended cutoff of 0.1% to discriminate patients with significantly different cumulative-incidence of relapse (-CIR- HR:0.71, P < 0.001) and overall survival (HR: 0.73, P = 0.001), but uncovered the limited prognostic value of MFC based MRD in multivariate and recursive partitioning models including other clinical, genetic and treatment related factors. Virtually all aspects related with methodological, interpretation, and reporting of MFC based MRD testing impacted in its ability to discriminate patients with different CIR. Thus, this study demonstrated that "real-world" assessment of MRD using MFC is prognostic in patients at first remission, and urges greater standardization for improved risk-stratification toward clinical decisions in AML.

引用

页码：2358 / 2370

页数：13

共 49 条

[1] Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML [J].

Anthias, C. ;

Dignan, F. L. ;

Morilla, R. ;

Morilla, A. ;

Ethell, M. E. ;

Potter, M. N. ;

Shaw, B. E. .

BONE MARROW TRANSPLANTATION, 2014, 49 (05) :679-683

[2] Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? [J].

Araki, Daisuke ;

Wood, Brent L. ;

Othus, Megan ;

Radich, Jerald P. ;

Halpern, Anna B. ;

Zhou, Yi ;

Mielcarek, Marco ;

Estey, Elihu H. ;

Appelbaum, Frederick R. ;

Walter, Roland B. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04) :329-+

[3] Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation [J].

Bastos-Oreiro, Mariana ;

Perez-Corral, Ana ;

Martinez-Laperche, Carolina ;

Bento, Leyre ;

Pascual, Cristina ;

Kwon, Mi ;

Balsalobre, Pascual ;

Munoz, Cristina ;

Buces, Elena ;

Serrano, David ;

Gayoso, Jorge ;

Buno, Ismael ;

Anguita, Javier ;

Luis Diez-Martin, Jose .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (03) :239-246

[4] Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis [J].

Bleyzac, N. ;

Cuzzubbo, D. ;

Renard, C. ;

Garnier, N. ;

Dubois, V. ;

Domenech, C. ;

Goutagny, M-P ;

Plesa, A. ;

Grardel, N. ;

Goutelle, S. ;

Janoly-Dumenil, A. ;

Bertrand, Y. .

BONE MARROW TRANSPLANTATION, 2016, 51 (05) :698-704

[5] Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible? [J].

Brooimans, Rik A. ;

van der Velden, Vincent H. J. ;

Boeckx, Nancy ;

Slomp, Jennita ;

Preijers, Frank ;

te Marvelde, Jeroen G. ;

Van, Ngoc M. ;

Heijs, Antoinette ;

Huys, Erik ;

van der Holt, Bronno ;

de Greef, Georgine E. ;

Kelder, Angele ;

Schuurhuis, Gerrit Jan .

LEUKEMIA RESEARCH, 2019, 76 :39-47

[6] The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia [J].

Buccisano, F. ;

Maurillo, L. ;

Gattei, V. ;

Del Poeta, G. ;

Del Principe, M. I. ;

Cox, M. C. ;

Panetta, P. ;

Consalvo, M. Irno ;

Mazzone, C. ;

Neri, B. ;

Ottaviani, L. ;

Fraboni, D. ;

Tamburini, A. ;

Lo-Coco, F. ;

Amadori, S. ;

Venditti, A. .

LEUKEMIA, 2006, 20 (10) :1783-1789

[7] Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients [J].

Buccisano, F. ;

Maurillo, L. ;

Piciocchi, A. ;

Del Principe, M. I. ;

Sarlo, C. ;

Cefalo, M. ;

Ditto, C. ;

Di Veroli, A. ;

De Santis, G. ;

Consalvo, M. Irno ;

Fraboni, D. ;

Panetta, P. ;

Palomba, P. ;

Attrotto, C. ;

Del Poeta, G. ;

Sconocchia, G. ;

Lo-Coco, F. ;

Amadori, S. ;

Venditti, A. .

ANNALS OF HEMATOLOGY, 2015, 94 (08) :1319-1326

[8] Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia [J].

Buccisano, Francesco ;

Maurillo, Luca ;

Spagnoli, Alessandra ;

Del Principe, Maria Ilaria ;

Fraboni, Daniela ;

Panetta, Paola ;

Ottone, Tiziana ;

Consalvo, Maria Irno ;

Lavorgna, Serena ;

Bulian, Pietro ;

Ammatuna, Emanuele ;

Angelini, Daniela F. ;

Diamantini, Adamo ;

Campagna, Selenia ;

Ottaviani, Licia ;

Sarlo, Chiara ;

Gattei, Valter ;

Del Poeta, Giovanni ;

Arcese, William ;

Amadori, Sergio ;

Lo Coco, Francesco ;

Venditti, Adriano .

BLOOD, 2010, 116 (13) :2295-2303

[9] Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis [J].

Buckley, Sarah A. ;

Wood, Brent L. ;

Othus, Megan ;

Hourigan, Christopher S. ;

Ustun, Celalettin ;

Linden, Michael A. ;

DeFor, Todd E. ;

Malagola, Michele ;

Anthias, Chloe ;

Valkova, Veronika ;

Kanakry, Christopher G. ;

Gruhn, Bernd ;

Buccisano, Francesco ;

Devine, Beth ;

Walter, Roland B. .

HAEMATOLOGICA, 2017, 102 (05) :865-873

[10] REPORT OF THE NATIONAL CANCER INSTITUTE-SPONSORED WORKSHOP ON DEFINITIONS OF DIAGNOSIS AND RESPONSE IN ACUTE MYELOID-LEUKEMIA [J].

CHESON, BD ;

CASSILETH, PA ;

HEAD, DR ;

SCHIFFER, CA ;

BENNETT, JM ;

BLOOMFIELD, CD ;

BRUNNING, R ;

GALE, RP ;

GREVER, MR ;

KEATING, MJ ;

SAWITSKY, A ;

STASS, S ;

WEINSTEIN, H ;

WOODS, WG .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) :813-819

← 1 2 3 4 5 →